VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
KALAKALA BIO, Inc.
$3.61$79M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksKALAP/E History

KALA logoKALA BIO, Inc. (KALA) P/E Ratio History

Deep Value

Trading at -1.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2023–2023

Current P/E (TTM)
-1.1x
-100% vs 5Y avg
5Y Avg P/E
9118.8x
Median 9118.8x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$-2.41
Price$3.61
Earnings YieldN/A
EPS Growth (1Y)52.6%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, KALA BIO, Inc. (KALA) trades at a price-to-earnings ratio of -1.1x, with a stock price of $3.61 and trailing twelve-month earnings per share of $-2.41.

The current P/E is 100% below its 5-year average of 9118.8x. Over the past five years, KALA's P/E has ranged from a low of 9118.8x to a high of 9118.8x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, KALA trades at a 105% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, KALA trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KALA DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

KALA Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-1.1vs22.1
-105%
Below Sector
vs. S&P 500
-1.1vs24.4
-104%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 53% EPS growth (1Y)

KALA P/E vs Peers

Ophthalmology Therapies and Delivery peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
LNTH logoLNTHLantheus Holdings, Inc.
$7B30.5Lowest-Best-22%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

KALA Historical P/E Data (2023–2023)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2023 Q2Jun 30 2023$729.50$0.089118.8x+0%

Average P/E for displayed period: 9118.8x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

3+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

KALA — Frequently Asked Questions

Quick answers to the most common questions about buying KALA stock.

What is KALA's P/E ratio?

KALA BIO, Inc. (KALA) trailing twelve-month P/E ratio is -1.1x, based on TTM diluted EPS of $-2.41. The 5-year average P/E is 9118.8x and the historical range spans 9118.8x to 9118.8x.

Is KALA stock overvalued or undervalued?

KALA trades at -1.1x P/E, below its 5-year average of 9118.8x. At the 0th percentile of its historical range (9118.8x–9118.8x), the stock is priced at a discount to its own history.

Is KALA stock expensive?

No, KALA is not expensive on a historical basis. The current P/E of -1.1x is below the 5-year average of 9118.8x and sits at the 0th percentile of its valuation range.

What is KALA's historical P/E range?

Over the past 5 years, KALA's P/E ratio has ranged from 9118.8x to 9118.8x, with a median of 9118.8x and an average of 9118.8x. The current P/E of -1.1x places the stock at the 0th percentile of this range. Full historical data spans 2023–2023.

How does KALA's P/E compare to the S&P 500?

KALA trades at -1.1x P/E versus the S&P 500 median of 24.4x. The 105% discount to the market suggests lower growth expectations or perceived higher risk.

How does KALA's valuation compare to Healthcare peers?

KALA BIO, Inc. P/E of -1.1x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is KALA's PEG ratio?

KALA PEG ratio is N/A, based on a P/E of -1.1x and EPS growth of 52.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is KALA's earnings yield?

KALA earnings yield is N/A, the inverse of its -1.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

KALA P/E Ratio History (2023–2023)

Quarterly valuation multiple from closing price and trailing EPS

Current9118.8x
Period Avg9118.8x
Range9118.8x - 9118.8x
Change+0%
1 quartersJun 30, 2023 - Jun 30, 2023